Alexis Borisy, IDRx co-founder
August 2, 2022 06:30 AM EDTUpdated 07:22 AM
Financing
Startups

New biotech from Alex­is Borisy will test Mer­ck KGaA, Blue­print can­cer drug com­bo in bid to ful­fill Gleevec promise

Kyle LaHucik

Senior Reporter

Alex­is Borisy and Ben Aus­pitz want to be in­tel­li­gent with their lat­est biotech, not “stu­pid.”

That’s in the words of Borisy, the re­peat biotech en­tre­pre­neur …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Among phar­ma CEOs, the IRA now and the IRA lat­er get very dif­fer­ent re­ac­tions

Bris­tol My­ers restarts ra­dio­phar­ma­ceu­ti­cal Phase 3 tri­al, but de­lays read­out by one year

An­drew Left, short sell­er who cam­paigned against Valeant, is ac­cused of fraud by SEC

Up­dat­ed: With cost-cut­ting un­der­way, Bris­tol My­ers rais­es guid­ance, touts Phase 3 win and scraps an­oth­er

Com­pound­ed weight loss drugs have re­sult­ed in mis­dos­ing, hos­pi­tal­iza­tions, FDA warns

sponsored

Crit­i­cal Junc­tures in Gene Ther­a­py Clin­i­cal Ma­te­r­i­al Man­u­fac­tur­ing: Where Do I Start? And Will It Work?

A service from the Financial Times